9.60
+0(+0.00%)
Currency In USD
| Previous Close | 9.6 |
| Open | 9.6 |
| Day High | 9.6 |
| Day Low | 9.6 |
| 52-Week High | 20.02 |
| 52-Week Low | 4.82 |
| Volume | 811,056 |
| Average Volume | 119,124 |
| Market Cap | 97.22M |
| PE | -4.42 |
| EPS | -2.17 |
| Moving Average 50 Days | 8.91 |
| Moving Average 200 Days | 8.83 |
| Change | 0 |
If you invested $1000 in OptiNose, Inc. (OPTN) since IPO date, it would be worth $33.68 as of July 07, 2025 at a share price of $9.6. Whereas If you bought $1000 worth of OptiNose, Inc. (OPTN) shares 5 years ago, it would be worth $140.97 as of July 07, 2025 at a share price of $9.6.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Optinose Cancels Fourth Quarter and Full Year 2024 Earnings Call
GlobeNewswire Inc.
Mar 20, 2025 1:45 AM GMT
YARDLEY, Pa., March 19, 2025 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the cancellation of its earnings conference call fo
Optinose Announces Reporting Date for Fourth Quarter and Full Year 2024 Financial Results
GlobeNewswire Inc.
Mar 11, 2025 8:15 PM GMT
Conference Call and Webcast to be held March 20, 2025, at 8:00 a.m. Eastern TimeYARDLEY, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy
Optinose Announces Preliminary Unaudited Fourth Quarter 2024 XHANCE Net Revenue of $22.4 Million
GlobeNewswire Inc.
Jan 15, 2025 12:00 PM GMT
Preliminary XHANCE prescription growth rate from third quarter to fourth quarter 2024 estimated to be approximately 20%YARDLEY, Pa., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by e
Data not available